468 related articles for article (PubMed ID: 34593302)
1. Tau and MAPT genetics in tauopathies and synucleinopathies.
Leveille E; Ross OA; Gan-Or Z
Parkinsonism Relat Disord; 2021 Sep; 90():142-154. PubMed ID: 34593302
[TBL] [Abstract][Full Text] [Related]
2. Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies.
Langerscheidt F; Wied T; Al Kabbani MA; van Eimeren T; Wunderlich G; Zempel H
J Neurol; 2024 Jun; 271(6):2992-3018. PubMed ID: 38554150
[TBL] [Abstract][Full Text] [Related]
3. Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration.
Li W; Li JY
Transl Neurodegener; 2024 Mar; 13(1):16. PubMed ID: 38528629
[TBL] [Abstract][Full Text] [Related]
4. Disentangling the role of the tau gene locus in sporadic tauopathies.
Vandrovcova J; Anaya F; Kay V; Lees A; Hardy J; de Silva R
Curr Alzheimer Res; 2010 Dec; 7(8):726-34. PubMed ID: 20704554
[TBL] [Abstract][Full Text] [Related]
5. Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies.
Silva MC; Haggarty SJ
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255694
[TBL] [Abstract][Full Text] [Related]
6. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
7. The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy.
Zhang CC; Xing A; Tan MS; Tan L; Yu JT
Mol Neurobiol; 2016 Sep; 53(7):4893-904. PubMed ID: 26363795
[TBL] [Abstract][Full Text] [Related]
8. Interface between tauopathies and synucleinopathies: a tale of two proteins.
Galpern WR; Lang AE
Ann Neurol; 2006 Mar; 59(3):449-58. PubMed ID: 16489609
[TBL] [Abstract][Full Text] [Related]
9. Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies.
Forrest SL; Kril JJ; Stevens CH; Kwok JB; Hallupp M; Kim WS; Huang Y; McGinley CV; Werka H; Kiernan MC; Götz J; Spillantini MG; Hodges JR; Ittner LM; Halliday GM
Brain; 2018 Feb; 141(2):521-534. PubMed ID: 29253099
[TBL] [Abstract][Full Text] [Related]
10. MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Strang KH; Golde TE; Giasson BI
Lab Invest; 2019 Jul; 99(7):912-928. PubMed ID: 30742061
[TBL] [Abstract][Full Text] [Related]
11. Untangling the tau gene association with neurodegenerative disorders.
Pittman AM; Fung HC; de Silva R
Hum Mol Genet; 2006 Oct; 15 Spec No 2():R188-95. PubMed ID: 16987883
[TBL] [Abstract][Full Text] [Related]
12. The role of tau (MAPT) in frontotemporal dementia and related tauopathies.
Rademakers R; Cruts M; van Broeckhoven C
Hum Mutat; 2004 Oct; 24(4):277-95. PubMed ID: 15365985
[TBL] [Abstract][Full Text] [Related]
13. Genetic and sporadic forms of tauopathies-TAU as a disease driver for the majority of patients but the minority of tauopathies.
Zempel H
Cytoskeleton (Hoboken); 2024 Jan; 81(1):66-70. PubMed ID: 37795931
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration.
Josephs KA; Tsuboi Y; Cookson N; Watt H; Dickson DW
Arch Neurol; 2004 Oct; 61(10):1579-84. PubMed ID: 15477512
[TBL] [Abstract][Full Text] [Related]
15. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
[TBL] [Abstract][Full Text] [Related]
16. The human MAPT locus generates circular RNAs.
Welden JR; van Doorn J; Nelson PT; Stamm S
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2753-2760. PubMed ID: 29729314
[TBL] [Abstract][Full Text] [Related]
17. MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration.
Simone R; Javad F; Emmett W; Wilkins OG; Almeida FL; Barahona-Torres N; Zareba-Paslawska J; Ehteramyan M; Zuccotti P; Modelska A; Siva K; Virdi GS; Mitchell JS; Harley J; Kay VA; Hondhamuni G; Trabzuni D; Ryten M; Wray S; Preza E; Kia DA; Pittman A; Ferrari R; Manzoni C; Lees A; Hardy JA; Denti MA; Quattrone A; Patani R; Svenningsson P; Warner TT; Plagnol V; Ule J; de Silva R
Nature; 2021 Jun; 594(7861):117-123. PubMed ID: 34012113
[TBL] [Abstract][Full Text] [Related]
18. Tau alternative splicing in familial and sporadic tauopathies.
Niblock M; Gallo JM
Biochem Soc Trans; 2012 Aug; 40(4):677-80. PubMed ID: 22817715
[TBL] [Abstract][Full Text] [Related]
19. The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features.
Kara E; Ling H; Pittman AM; Shaw K; de Silva R; Simone R; Holton JL; Warren JD; Rohrer JD; Xiromerisiou G; Lees A; Hardy J; Houlden H; Revesz T
Neurobiol Aging; 2012 Sep; 33(9):2231.e7-2231.e14. PubMed ID: 22595371
[TBL] [Abstract][Full Text] [Related]
20. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
